FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma

Amit Mahipal, Sri Harsha Tella, Anuhya Kommalapati, Daniel Anaya, Richard Kim

Research output: Contribution to journalReview article

Abstract

Cholangiocarcinoma is the most common aggressive biliary tract malignancy with dismal prognosis. Though surgical resection of the primary tumors yields better prognosis, majority of patients present at advanced, inoperable stages rendering systemic therapy as the only option. A significant progress has been made in understanding the cholangiocarcinoma tumorigenesis and molecular markers over the last decade, which opens doors to precision medicine in this dismal cancer. Intrahepatic cholangiocarcinomas are most likely to harbor mutations in isocitrate dehydrogenase genes (IDH1, IDH2), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), Eph receptor 2 (EPHA2), and BAP1 (gene involved in chromatin remodeling) genes, whereas ARID1B, ELF3, PBRM1, cAMP dependent protein kinase (PRKACA, and PRKACB) genetic mutations were implicated more commonly in distal and perihilar subtypes. Genomic studies have shown that FGFR2 aberrations are implicated in approximately 15% of intrahepatic cholangiocarcinomas, which make FGFR2 aberrations (Achilles heel) as potential novel targets in the management of cholangiocarcinoma. The current review comprehensively focuses on the role of FGFR2 inhibition either alone or in combination with other targeted therapy that act on down-stream and alternate kinase pathways in cholangiocarcinoma.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCancer Treatment Reviews
Volume78
DOIs
StatePublished - Aug 1 2019

Fingerprint

Cholangiocarcinoma
EphA1 Receptor
Genes
Isocitrate Dehydrogenase
Fibroblast Growth Factor Receptors
Neoplasms
Precision Medicine
Mutation
Chromatin Assembly and Disassembly
Biliary Tract
Cyclic AMP-Dependent Protein Kinases
Carcinogenesis
Phosphotransferases
Therapeutics

Keywords

  • ARQ 087
  • BGJ398
  • Cholangiocarcinoma
  • FGFR
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

FGFR2 genomic aberrations : Achilles heel in the management of advanced cholangiocarcinoma. / Mahipal, Amit; Tella, Sri Harsha; Kommalapati, Anuhya; Anaya, Daniel; Kim, Richard.

In: Cancer Treatment Reviews, Vol. 78, 01.08.2019, p. 1-7.

Research output: Contribution to journalReview article

Mahipal, Amit ; Tella, Sri Harsha ; Kommalapati, Anuhya ; Anaya, Daniel ; Kim, Richard. / FGFR2 genomic aberrations : Achilles heel in the management of advanced cholangiocarcinoma. In: Cancer Treatment Reviews. 2019 ; Vol. 78. pp. 1-7.
@article{82622f17f5c24f0da0cfb72ef0c5febe,
title = "FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma",
abstract = "Cholangiocarcinoma is the most common aggressive biliary tract malignancy with dismal prognosis. Though surgical resection of the primary tumors yields better prognosis, majority of patients present at advanced, inoperable stages rendering systemic therapy as the only option. A significant progress has been made in understanding the cholangiocarcinoma tumorigenesis and molecular markers over the last decade, which opens doors to precision medicine in this dismal cancer. Intrahepatic cholangiocarcinomas are most likely to harbor mutations in isocitrate dehydrogenase genes (IDH1, IDH2), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), Eph receptor 2 (EPHA2), and BAP1 (gene involved in chromatin remodeling) genes, whereas ARID1B, ELF3, PBRM1, cAMP dependent protein kinase (PRKACA, and PRKACB) genetic mutations were implicated more commonly in distal and perihilar subtypes. Genomic studies have shown that FGFR2 aberrations are implicated in approximately 15{\%} of intrahepatic cholangiocarcinomas, which make FGFR2 aberrations (Achilles heel) as potential novel targets in the management of cholangiocarcinoma. The current review comprehensively focuses on the role of FGFR2 inhibition either alone or in combination with other targeted therapy that act on down-stream and alternate kinase pathways in cholangiocarcinoma.",
keywords = "ARQ 087, BGJ398, Cholangiocarcinoma, FGFR, Targeted therapy",
author = "Amit Mahipal and Tella, {Sri Harsha} and Anuhya Kommalapati and Daniel Anaya and Richard Kim",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.ctrv.2019.06.003",
language = "English (US)",
volume = "78",
pages = "1--7",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - FGFR2 genomic aberrations

T2 - Achilles heel in the management of advanced cholangiocarcinoma

AU - Mahipal, Amit

AU - Tella, Sri Harsha

AU - Kommalapati, Anuhya

AU - Anaya, Daniel

AU - Kim, Richard

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Cholangiocarcinoma is the most common aggressive biliary tract malignancy with dismal prognosis. Though surgical resection of the primary tumors yields better prognosis, majority of patients present at advanced, inoperable stages rendering systemic therapy as the only option. A significant progress has been made in understanding the cholangiocarcinoma tumorigenesis and molecular markers over the last decade, which opens doors to precision medicine in this dismal cancer. Intrahepatic cholangiocarcinomas are most likely to harbor mutations in isocitrate dehydrogenase genes (IDH1, IDH2), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), Eph receptor 2 (EPHA2), and BAP1 (gene involved in chromatin remodeling) genes, whereas ARID1B, ELF3, PBRM1, cAMP dependent protein kinase (PRKACA, and PRKACB) genetic mutations were implicated more commonly in distal and perihilar subtypes. Genomic studies have shown that FGFR2 aberrations are implicated in approximately 15% of intrahepatic cholangiocarcinomas, which make FGFR2 aberrations (Achilles heel) as potential novel targets in the management of cholangiocarcinoma. The current review comprehensively focuses on the role of FGFR2 inhibition either alone or in combination with other targeted therapy that act on down-stream and alternate kinase pathways in cholangiocarcinoma.

AB - Cholangiocarcinoma is the most common aggressive biliary tract malignancy with dismal prognosis. Though surgical resection of the primary tumors yields better prognosis, majority of patients present at advanced, inoperable stages rendering systemic therapy as the only option. A significant progress has been made in understanding the cholangiocarcinoma tumorigenesis and molecular markers over the last decade, which opens doors to precision medicine in this dismal cancer. Intrahepatic cholangiocarcinomas are most likely to harbor mutations in isocitrate dehydrogenase genes (IDH1, IDH2), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), Eph receptor 2 (EPHA2), and BAP1 (gene involved in chromatin remodeling) genes, whereas ARID1B, ELF3, PBRM1, cAMP dependent protein kinase (PRKACA, and PRKACB) genetic mutations were implicated more commonly in distal and perihilar subtypes. Genomic studies have shown that FGFR2 aberrations are implicated in approximately 15% of intrahepatic cholangiocarcinomas, which make FGFR2 aberrations (Achilles heel) as potential novel targets in the management of cholangiocarcinoma. The current review comprehensively focuses on the role of FGFR2 inhibition either alone or in combination with other targeted therapy that act on down-stream and alternate kinase pathways in cholangiocarcinoma.

KW - ARQ 087

KW - BGJ398

KW - Cholangiocarcinoma

KW - FGFR

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85067892384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067892384&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2019.06.003

DO - 10.1016/j.ctrv.2019.06.003

M3 - Review article

C2 - 31255945

AN - SCOPUS:85067892384

VL - 78

SP - 1

EP - 7

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -